GLP-1 receptor agonist · Evidence-led, sources cited
Saxenda (Liraglutide)
Licensed in the UK for weight management. Daily injection.
How it works
Liraglutide is a daily GLP-1 injection that reduces appetite. It predates the weekly options and is still prescribed.
Published dosing
Per the Saxenda SmPC, the dose is increased gradually over weeks from a low starting dose toward a maintenance dose, as tolerated and as your prescriber directs.
Common side effects
Commonly reported effects per the SmPC are gastrointestinal: nausea, vomiting, diarrhoea, constipation.
What the evidence shows
The SCALE trials supported its weight-management licence; average weight loss is generally lower than the newer weekly agents.